Key Segmentation:
By Drug Class
-
NSAIDs
-
Corticosteroids
-
Anticonvulsants
-
Opioids
-
Others
By Type
-
Acute Sciatica
-
Chronic Sciatica
By Route of Administration
-
Oral
-
Transdermal
-
Injectable
By Non-Pharmacological Modality
-
Physical & Exercise Therapy
-
Radiofrequency Ablation
-
Surgery
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Endo International, Johnson & Johnson, Pfizer, Abbott, Bayer, Novartis, GlaxoSmithKline, Bristol Myers Squibb, Scilex Holding Company, and Vertex Pharmaceuticals, among others.
The development of targeted injectables for radicular pain and the expansion of minimally invasive, image-guided procedures represent the two most significant opportunities shaping the market's next phase of growth.
Growth is primarily driven by the rising prevalence of sciatica in an ageing, increasingly sedentary population, combined with growing demand for effective non-opioid treatment options.
By Drug Class, NSAIDs dominated the market with a 39.47% share in 2025, reflecting their wide availability, low cost, and established first-line role in relieving sciatica pain.
North America dominated the market with a 44.20% share in 2025, supported by advanced treatment options, high healthcare spending, and a large interventional pain community, led by the United States.
